Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients

Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients
Parkinsonism Relat Disord. 2021 Apr 28;87:25-31. doi: 10.1016/j.parkreldis.2021.04.012. Online ahead of print.ABSTRACTINTRODUCTION: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated with Parkinson's disease psychosis (PDP). We present durability of response with pimavanserin in patients with PDP for an additional 4 weeks of treatment.METHODS: This was an open-label extension (OLE) study in patients previously completing one ... read more
Source: PubMedPublished on 2021-05-02By Stuart H Isaacson